Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from P...
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
About this item
Full title
Author / Creator
Simpson, Eric L. , Prajapati, Vimal H. , Leshem, Yael A. , Chovatiya, Raj , de Bruin-Weller, Marjolein S. , Ständer, Sonja , Pink, Andrew E. , Calimlim, Brian M. , Lee, Wan-Ju , Teixeira, Henrique , Ladizinski, Barry , Hu, Xiaofei , Yang, Yang , Liu, Yingyi , Liu, Meng , Grada, Ayman , Platt, Andrew M. and Silverberg, Jonathan I.
Publisher
Cheshire: Springer Healthcare
Journal title
Language
English
Formats
Publication information
Publisher
Cheshire: Springer Healthcare
Subjects
More information
Scope and Contents
Contents
Introduction
Atopic dermatitis (AD) is characterized by intense itch and other symptoms that negatively impact quality of life (QoL). This study evaluates the effect of upadacitinib (an oral selective Janus kinase inhibitor) monotherapy on patient-reported outcomes (PROs) among adults and adolescents with moderate-to-severe AD over 16 weeks.
...
Alternative Titles
Full title
Upadacitinib Rapidly Improves Patient-Reported Outcomes in Atopic Dermatitis: 16-Week Results from Phase 3 Clinical Trials (Measure Up 1 and 2)
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_d13086b1bc984adeabc8518d220ee7d9
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_d13086b1bc984adeabc8518d220ee7d9
Other Identifiers
ISSN
2193-8210
E-ISSN
2190-9172
DOI
10.1007/s13555-024-01157-5
